CO5271686A1 - Nuevo uso de (r)-(-)-2-[5-(4-flurofenil)-3-piridilmetil- aminometil]-cromano y de sus sales aceptables para uso fisiologico - Google Patents

Nuevo uso de (r)-(-)-2-[5-(4-flurofenil)-3-piridilmetil- aminometil]-cromano y de sus sales aceptables para uso fisiologico

Info

Publication number
CO5271686A1
CO5271686A1 CO01019802A CO01019802A CO5271686A1 CO 5271686 A1 CO5271686 A1 CO 5271686A1 CO 01019802 A CO01019802 A CO 01019802A CO 01019802 A CO01019802 A CO 01019802A CO 5271686 A1 CO5271686 A1 CO 5271686A1
Authority
CO
Colombia
Prior art keywords
pyridylmethyl
cromano
amynometil
flurophenyl
acceptable salts
Prior art date
Application number
CO01019802A
Other languages
English (en)
Inventor
Gerd Bartoszyk
Hermann Russ
Seyfried Christophh
Frank Weber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CO5271686A1 publication Critical patent/CO5271686A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1 Una composición farmacéutica que comprende, como principios activos, (i) (R)-(-)-2-[5-(4-florofenil)-3-piridilmetil-aminometil]-cromano o una sal del mismo aceptable para uso fisiológico, y (ii) al menos una droga contra el Parkinson, en combinación con uno o más excipientes aceptables para el uso farmacéutico. <EMI FILE="01019802_1" ID="1" IMF=JPEG >
CO01019802A 2000-03-10 2001-03-12 Nuevo uso de (r)-(-)-2-[5-(4-flurofenil)-3-piridilmetil- aminometil]-cromano y de sus sales aceptables para uso fisiologico CO5271686A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00104531 2000-03-10

Publications (1)

Publication Number Publication Date
CO5271686A1 true CO5271686A1 (es) 2003-04-30

Family

ID=8168017

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01019802A CO5271686A1 (es) 2000-03-10 2001-03-12 Nuevo uso de (r)-(-)-2-[5-(4-flurofenil)-3-piridilmetil- aminometil]-cromano y de sus sales aceptables para uso fisiologico

Country Status (29)

Country Link
US (1) US7928128B2 (es)
EP (2) EP1645273A3 (es)
JP (1) JP4901046B2 (es)
KR (1) KR100830139B1 (es)
CN (1) CN1188123C (es)
AR (1) AR033807A1 (es)
AT (1) ATE307578T1 (es)
AU (2) AU2001230222C1 (es)
BR (1) BR0109119A (es)
CA (1) CA2402402C (es)
CO (1) CO5271686A1 (es)
CZ (1) CZ301807B6 (es)
DE (1) DE60114419T2 (es)
DK (1) DK1299099T3 (es)
ES (1) ES2251460T3 (es)
HK (1) HK1054198B (es)
HU (1) HU229309B1 (es)
ME (1) MEP5608A (es)
MX (1) MXPA02008800A (es)
MY (1) MY136976A (es)
NO (1) NO329583B1 (es)
PL (1) PL200781B1 (es)
RS (1) RS51316B (es)
RU (1) RU2278663C2 (es)
SI (1) SI1299099T1 (es)
SK (1) SK286933B6 (es)
UA (1) UA73981C2 (es)
WO (1) WO2001068063A2 (es)
ZA (1) ZA200208133B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
CA2455621C (en) * 2001-07-26 2010-11-16 Merck Patent Gesellschaft Mit Beschraenkter Haftung Use of (r/s)-(-/+) or (s)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane for the treatment of extrapyramidal movement disorders
AU2002331229B2 (en) * 2001-09-19 2008-05-15 Merck Patent Gmbh Novel use of substituted aminomethyl chromans
CN101198328B (zh) * 2005-06-21 2011-04-06 默克专利股份有限公司 含有（r）-（-）-2-[5-（4-氟苯基）-3-吡啶基甲基氨基甲基]苯并二氢吡喃的固体药物制剂
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
CN108937972A (zh) * 2018-06-08 2018-12-07 青岛大学附属医院 一种多特征融合的就诊用户情绪监控方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE69123090D1 (de) * 1990-07-06 1996-12-19 Yoshitomi Pharmaceutical Kondensierte Thiophenverbindungen und deren Verwendung
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) * 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
EP0630238A4 (en) * 1992-03-11 1995-05-24 Interneuron Pharma REDUCTION OF FLUCTUATIONS AFTER MEALS OF PLASMIC CONCENTRATIONS OF LARGE NEUTRAL ACIDS.
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
JPH08503448A (ja) * 1992-12-07 1996-04-16 メレルダウファーマス−ティカルズ インコーポレイテッド ５ｈｔ▲下１▼▲ａ▼受容体アゴニストによる不随意運動の処置
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
AU684730B2 (en) * 1993-11-19 1998-01-08 Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations, The Octahydrobenzo{f}quinoline-based receptor agonists and antagonists
IL114027A (en) 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
DE69524528T2 (de) * 1994-10-14 2002-08-01 Merck Patent Gmbh ZNS wirksames (R)-(-)-2-[5-(4-Fluorophenyl)-3-pyridylmethylaminomethyl]chroman
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) * 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
EP0839144B1 (en) * 1995-07-13 2001-09-19 Knoll GmbH Piperazine derivatives as therapeutic agents
US5670667A (en) * 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) * 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) * 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
DE69819266T2 (de) * 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
AU2981099A (en) * 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
TR200002671T2 (tr) * 1998-03-17 2000-12-21 Pfizer Products Inc. Bisiklo(2.2.1)Heptanlar ve ilgili bileşikler
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
CA2402402C (en) 2013-01-22
RU2278663C2 (ru) 2006-06-27
UA73981C2 (en) 2005-10-17
HK1054198A1 (en) 2003-11-21
SK286933B6 (sk) 2009-07-06
EP1645273A3 (en) 2006-04-19
ZA200208133B (en) 2004-04-01
SK12642002A3 (sk) 2003-02-04
CA2402402A1 (en) 2001-09-20
CZ20022951A3 (cs) 2003-01-15
EP1645273A2 (en) 2006-04-12
DK1299099T3 (da) 2006-03-06
BR0109119A (pt) 2003-06-03
EP1299099A2 (en) 2003-04-09
AR033807A1 (es) 2004-01-07
ATE307578T1 (de) 2005-11-15
PL356428A1 (en) 2004-06-28
DE60114419T2 (de) 2006-07-27
PL200781B1 (pl) 2009-02-27
US7928128B2 (en) 2011-04-19
HUP0300079A2 (en) 2003-05-28
NO20024291L (no) 2002-09-09
US20030181486A1 (en) 2003-09-25
NO20024291D0 (no) 2002-09-09
AU2001230222C1 (en) 2005-09-22
RU2002127006A (ru) 2004-03-27
KR100830139B1 (ko) 2008-05-20
MXPA02008800A (es) 2003-02-12
EP1299099B1 (en) 2005-10-26
ES2251460T3 (es) 2006-05-01
CN1188123C (zh) 2005-02-09
AU2001230222B2 (en) 2005-03-17
MY136976A (en) 2008-12-31
WO2001068063A3 (en) 2002-05-10
JP4901046B2 (ja) 2012-03-21
RS51316B (sr) 2010-12-31
DE60114419D1 (de) 2005-12-01
WO2001068063A2 (en) 2001-09-20
SI1299099T1 (sl) 2006-04-30
HU229309B1 (en) 2013-10-28
MEP5608A (xx) 2010-02-10
CN1416344A (zh) 2003-05-07
YU67402A (sh) 2006-01-16
CZ301807B6 (cs) 2010-06-30
KR20030016236A (ko) 2003-02-26
NO329583B1 (no) 2010-11-15
JP2004522692A (ja) 2004-07-29
HK1054198B (zh) 2005-05-20
AU3022201A (en) 2001-09-24

Similar Documents

Publication Publication Date Title
ES2524458T3 (es) DNasa para el tratamiento de la subfertilidad masculina
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
AR025055A1 (es) Composiciones farmaceuticas
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
UY29182A1 (es) &#34;derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones&#34;
BR0015605A (pt) Composição e uso
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
BR0309544A (pt) Preparação farmacêutica contendo oxicodona e naloxona
CL2008003939A1 (es) Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
BR9406893A (pt) Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids
RS50303B (sr) Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
AR023966A1 (es) Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
CO5271686A1 (es) Nuevo uso de (r)-(-)-2-[5-(4-flurofenil)-3-piridilmetil- aminometil]-cromano y de sus sales aceptables para uso fisiologico
AR031679A1 (es) Una composicion farmaceutica
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BR0306923A (pt) Composição farmacêutica para regeneração de tecidos hepáticos para tratamento de cirrose do fìgado uso de 5-(2-pirazinil) -4-metil-1,2-ditiol-3-tiona
AR052048A1 (es) Composiciones farmaceuticas para el tratamiento de la celulitis
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.

Legal Events

Date Code Title Description
FC Application refused